Stingray Bio Ltd

Stingray Bio is a new UK biotech launched in 2021 to exploit years of leading academic research linking LMTK3 to essential disease biology in breast and other cancers. Our discovery-stage programmes are progressing specific small-molecule inhibitors of LMTK3 kinase towards clinical application. Leveraging our founding team’s extensive knowledge in the structural biology, cellular and cancer pharmacology of LMTK3, we anticipate our novel cancer agents targeting this unexploited kinase will find application in diverse cancer types and therapeutic applications.